论文部分内容阅读
本文报告了1980年以来我们在细胞杂交技术及其应用研究中取得的各项阶段性成果。在细胞杂交技术方面,用分子量在1000、2000、4000、6000的PEG为融合介质,获得了中国仓鼠成纤维细胞Wg3-h、人HeLa细胞、人胃腺癌细胞SGC-T901的同种异核体,以及雄性麂肺细胞KIZ-7901-中国仓鼠成纤维细胞Wg3-h、中国仓鼠卵巢细胞CHO-人外周血港巴细胞、中国仓鼠卵巢细胞CHO-正常人骨髓细胞、中国仓鼠卵巢细胞CHO-白血病患者骨髓细胞的异种异核体,并成功地显示了上述各种细胞组合的PCC图象。获得了在体外长期传代培养的小鼠骨髓瘤细胞NS-1-Ag8-BALB／c小鼠脾脏淋巴细胞以及小鼠骨髓瘤细胞SP2／0-Ag14-免疫后的BALB／c小鼠脾脏淋巴细胞的种内杂种细胞系。在细胞杂交技术的应用方面,重点在诱导“熟前凝聚染色体”(PCC),分析白血病患者骨髓细胞的群体增殖潜能。并据以判断白血病患者病情进展、疗效和预后,以及制备分泌抗人C4单克隆抗体的杂交瘤细胞系。本文对PEG的融合性能、白血病患者PPI值升高的机制、杂交瘤细胞的亚克隆化等问题进行了初步探讨。
This article reports the various milestones we have achieved in cell-hybrid technology and its applications since 1980. In the aspect of cell hybridization technology, allogeneic nuclei of Chinese hamster fibroblasts Wg3-h, human HeLa cells and human gastric adenocarcinoma cells SGC-T901 were obtained by using PEG with molecular weights of 1000, 2000, 4000 and 6000 as the fusion medium , As well as male sundial cells KIZ-7901-Chinese hamster fibroblast Wg3-h, Chinese hamster ovary cells CHO-human peripheral blood monocytes, Chinese hamster ovary cells CHO-normal human bone marrow cells, Chinese hamster ovary cells CHO-leukemia Heterologous heterokaryons from patients with bone marrow cells and successfully demonstrated the PCC images of the various cell combinations described above. The long-term in vitro cultured mouse myeloma NS-1-Ag8-BALB / c mouse spleen lymphocytes and mouse myeloma SP2 / 0-Ag14-immunized BALB / c mouse spleen lymphocytes Of hybrid cell lines within the species. In the application of cell hybridization techniques, the focus is on inducing “premature ripening chromosomes” (PCC) and analyzing the population proliferation potential of bone marrow cells in patients with leukemia. According to the judgment of leukemia patients progression, efficacy and prognosis, as well as preparation of anti-human monoclonal antibody secreting monoclonal antibody cell line. In this paper, the fusion performance of PEG, the mechanism of elevated PPI in leukemia and the subclone of hybridoma cells were discussed.